The impairment of ubiquitin-proteasome system (UPS) is a cellular mechanism underlying the neurodegenerative process in Parkinson’s disease (PD). Glial cell line-derived neurotrophic factor (GDNF) is one of the most potent neurotrophic factors promoting the growth and survival of mesencephalic dopamine (DA) neurons. To investigate whether GDNF has neuroprotective effects in a PD model induced by UPS impairment we administered GDNF by osmotic pump in C57BL/6 mice after nigrostriatal lesions with stereotactic injection of proteasome inhibitor lactacystin in the middle forebrain bundle. We found that lactacystin injection severely injured the nigral DA neurons and reduced the striatal levels of DA and its metabolites, while prolonged administration of GDNF at a sustained moderate dose for two weeks can significantly attenuate the lactacystin-induced loss of nigral DA neurons and striatal DA levels by 31% and 40%, respectively. We also investigated the molecular mechanisms for the neuroprotective effects of GDNF showing that lactacystin administration can cause the phosphorylation of extracellular signal-regulated kinase (ERK), p38MAPK (p38), and the c-Jun N-terminal kinase (JNK), whereas GDNF treatment can further enhance the phosphorylation of ERK and Akt but reduce the levels of JNK and p38. These results indicate that prolonged treatment with GDNF can protect the nigral DA neurons from the UPS impairment-induced degeneration. Several signaling path-ways including p38, JNK, Akt and ERK molecules seem to play an important role in this neuroprotection by GDNF.
Get full access to this article
View all access options for this article.
References
1.
Raichur A, Vali S, Gorin F. Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson’s disease. Neuroscience142:859–870, 2006.
Wood-Kaczmar A, Gandhi S, Wood NW. Understanding the molecular causes of Parkinson’s disease. Trends Mol Med12:521–528, 2006.
4.
Harrower TP, Michell AW, Barker RA. Lewy bodies in Parkinson’s disease: protectors or perpetrators? Exp Neurol195:1–6, 2005.
5.
Shults CW. Lewy bodies. Proc Natl Acad Sci U S A103:1661–1668, 2006.
6.
Zhu X, Siedlak SL, Smith MA, Perry G, Chen SG. LRRK2 protein is a component of Lewy bodies. Ann Neuro60:617–618, 2006.
7.
Ardley HC, Robinson PA. The role of ubiquitin-protein ligases in neurodegenerative disease. Neurodegener Dis1:71–87, 2004.
8.
Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson’s disease. Mov Disord21:1806–1823, 2006.
9.
Li XP, Yang DH, Li L, Peng CG, Chen S, Le WD. Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures. Neurochem Int50:959–965, 2007.
10.
Zhang X, Xie W, Qu S, Pan T, Wang X, Le W. Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochem Biophys Res Commun333:544–549, 2005.
11.
Zhu W, Xie W, Pan T, Xu P, Jankovic J, Youdim M, Le W. Prevention and rescue of lactacystin induced nigrostriatal dopamine neurons degeneration by novel brain permeable iron chelators. FASEB J21: 3835–3844, 2007.
12.
Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson’s disease brain. J Chem Neuroanat21:277–288, 2001.
13.
Date I, Aoi M, Tomita S, Collins F, Ohmoto T. GDNF administration induces recovery of the nigrostriatal dopamine system both in young and aged parkinsonian mice. Neuroreport9:2365–2369, 1998.
14.
Schober A, Peterziel H, von Bartheld CS, Simon H, Krieglstein K, Unsicker K. GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-beta for its neuroprotective action. Neurobiol Dis25: 378–391, 2007.
15.
Shingo T, Date I, Yoshida H, Ohmoto T. Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson’s disease. J Neurosci Res69:946–954, 2002.
16.
Ding YM, Jaumotte JD, Signore AP, Zigmond MJ. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J Neurochem89:776–787, 2004.
17.
Smith MP, Cass WA. GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson’s disease. Neurosci Lett41: 259–263, 2007.
18.
Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG, Elias WJ, Laws ER, Dhawan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol59:459–466, 2006.
19.
Salvatore MF, Ai Y, Fischer B, Zhang AM, Grondin RC, Zhang Z, Gerhardt GA, Gash DM. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol202:497–505, 2006.
20.
Onyango IG, Tuttle JB, Bennett JP. Brain-derived growth factor and glial cell line-derived growth factor use distinct intracellular signaling pathways to protect PD cybrids from H2O2-induced neuronal death. Neurobiol Dis20:141–154, 2005.
21.
Villegas SN, Njaine B, Linden R, Carri NG. Glial-derived neurotrophic factor (GDNF) prevents ethanol (EtOH) induced B92 glial cell death by both PI3K/Akt and MEK/ERK signaling pathways. Brain Res Bull71: 116–126, 2006.
22.
Asada S, Daitoku H, Matsuzaki H, Saito T, Sudo T, Mukai H, Iwashita S, Kako K, Kishi T, Kasuya Y, Fukamizu A. Mitogen-activated protein kinases, Erk and p38, phosphorylate and regulate Foxo1. Cell Signal19:519–527, 2007.
23.
Chen RW, Lu XC, Yao C, Liao Z, Jiang ZG, Wei H, Ghanbari HA, Tortella FC, Dave JR. PAN-811 provides neuroprotection against glutamate toxicity by suppressing activation of JNK and p38 MAPK. Neurosci Lett422:64–67, 2007.
24.
Klintworth H, Newhouse K, Li T, Choi WS, Faigle R, Xia Z. Activation of c-Jun N-terminal protein kinase is a common mechanism underlying paraquat- and rotenone-induced dopaminergic cell apoptosis. Toxicol Sci97:149–162, 2007.
25.
Valable S, Bellail A, Lesné S, Liot G, Mackenzie ET, Vivien D, Bernaudin M, Petit E. 2003. Angiopoietin-1-induced PI3Kinase activation prevents neuronal apoptosis. FASEB J17:443–445.
26.
Zhang L, Zhou R, Xiang G. Stepholidine protects against H2O2 neurotoxicity in rat cortical neurons by activation of Akt. Neurosci Lett383:328–332, 2005.
27.
Lee ER, Kim JY, Kang YJ, Ahn JY, Kim JH, Kim BW, Choi HY, Jeong MY, Cho SG. Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis. Biochim Biophys Acta1763:958–968, 2006.
28.
Yoon SO, Kim MM, Park SJ, Kim D, Chung J, Chung AS. Selenite suppresses hydrogen peroxide-induced cell apoptosis through inhibition of ASK1/JNK and activation of PI3K/Akt pathways. FASEB J16:111–113, 2002.
29.
Pi R, Li W, Lee NT, Chan HH, Pu Y, Chan LN, Sucher NJ, Chang DC, Li M, Han Y. Minocycline prevents glutamate-induced apoptosis of cerebellar granule neurons by differential regulation of p38 and Akt pathways. J Neurochem91:1219–1230, 2004.
30.
Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates (2nd ed.). San Diego: Academic Press, pp112–236, 2001.
31.
Kirik D, Georgievska B, Rosenblad C, Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson’s disease. Eur J Neurosci13:1589–1599, 2001.
32.
Muthane U, Ramsay KA, Jiang H, Jackson-Lewis V, Donaldson D, Fernando S, Ferreira M, Przedborski S. Differences in nigral neuron number and sensitivity to 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp Neurol126:195–204, 1994.
33.
Bove J, Zhou C, Jackson-Lewis V, Taylor J, Chu Y, Rideout HJ, Wu DC, Kordower JH, Petrucelli L, Przedborski S. Proteasome inhibition and Parkinson’s disease modeling. Ann Neurol60:260–264, 2006.
34.
Pakkenberg B, Møller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry54:30–33, 1991.
35.
Kemppainen N, Roytta M, Collan Y, Ma SY, Hinkka S, Rinne JO. Unbiased morphological measurements show no neuronal loss in the substantia nigra in Alzheimer’s disease. Acta Neuropathol103:43–47, 2002.
36.
Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev21:245–273, 2001.
37.
Li XP, Peng CG, Li L, Ming M, Yang DH, Le WD. Glial cell-derived neurotrophic factor against proteasome inhibition-induced dopamine neuron degeneration by suppression of endoplasmic reticulum stress and caspase-3 activation. J Gerontola-Biol62:943–950, 2007.
38.
Tofaris GK, Layfield R, Spillantini MG. Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett509:22–26, 2001.
39.
McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem81:301–306, 2002.
40.
Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci27: 9220–9232, 2007.
41.
Tombes RM, Aue KL, Mikkelsen R, Valerie K, Wymann MP, Marshall CJ, McMahon M, Dent P. The mitogenactivated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem J330:1451–1460, 1998.
42.
Oh-hashi K, Maruyama W, Yi H, Takahashi T, Naoi M, Isobe K. Mitogen-activated protein kinase pathway mediates peroxynitrite-induced apoptosis in human dopaminergic neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun263:504–509, 1999.
43.
Nair VD, McNaught KS, González-Maeso J, Sealfon SC, Olanow CW. p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem281:39550–39560, 2006.
44.
Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ13:941–950, 2006.
45.
Miller FD, Pozniak CD, Walsh GS. Neuronal life and death: an essential role for the p53 family. Cell Death Differ7:880–888, 2000.
46.
Inamura N, Enokido Y, Hatanaka H. Involvement of c-Jun N-terminal kinase and caspase 3-like protease in DNA damage-induced, p53-mediated apoptosis of cultured mouse cerebellar granule neurons. Brain Res904:270–278, 2001.
